Kornimate/medical-research-clean huggingface dataset:
efficacy assessment of chinese herbal medicine jiangtang tiaozhi recipe treating participants with glucose and lipid metabolism disturbances

Conditions: Type2 Diabetes; Dyslipidemias

Summary: this study is a randomized, positive drug parallel-controlled clinical trial in participants with glucose and lipid metabolism disturbances. a total of 96 participants will be recruited for the study, all of whom are diagnosed as type 2 diabetes mellitus combined with dyslipidemia. the subjects will be divided randomly into two groups and treated with either jiangtang tiaozhi recipe or metformin. after 12 weeks of treatment, therapeutic effect of jiangtang tiaozhi recipe will be evaluated based on the changes of hba1c, fasting blood glucose, postprandial blood glucose, blood lipid, waist circumference, body mass index.

the diagnosis criteria of type 2 diabetes mellitus are in accordance to 1999 world health organization (who) diabetes diagnostic criteria. the diagnosis criteria of dyslipidemia are based on the guidelines for the prevention and treatment of dyslipidemia in chinese adults (2016, revision edition). the outcomes mainly include hba1c, fasting blood glucose, postprandial blood glucose, body weight, waist circumference, blood lipid and tcm symptom score.

Eligibility criteria:
inclusion criteria: 1. aged 18 to 70 years at the time of their consent; 2. diagnosed with type 2 diabetes; 3. tg≥1.7 mmol/l or ldl-c≥3.4 mmol/l; 4. bmi≥24.0 kg/m2 or male waist circumference≥90 cm, female waist circumference≥80 cm; 5. failed to reach the normal standards of blood glucose and lipids after diet control and exercise therapy before enrollment; 6. tcm syndrome differentiation as excess heat in the stomach and intestines syndrome; 7. signed informed consent. exclusion criteria: 1. type 1 diabetes, gestational diabetes, other special types of diabetes. 2. diabetic complications were the main symptoms, that is, patients with serious heart, lung, liver, kidney, brain complications or other serious primary diseases. 3. patients with diabetic ketoacidosis, hyperosmolar nonketotic diabetic coma, severe infection, and surgery in recent one month. 4. have a history of serious gastrointestinal diseases, or are suffering from serious gastrointestinal diseases, such as peptic ulcer, gastrointestinal bleeding, gastroparesis, pyloric stenosis, gastric shunt, etc.. 5. psychiatric patients, alcoholism and/or psychoactive substances, drug abusers and addicts. 6. pregnant, preparing for pregnancy or lactation. 7. patients who participated in other clinical studies within one month prior to participating in this study or were participating in other clinical studies. 8. according to the judgment of the researcher, other diseases or conditions that reduce the possibility of enrollment or complicate the enrollment, such as frequent changes in working environment and unstable living environment, are likely to cause loss of follow-up.

Keywords: type 2 diabetes mellitus dyslipidemias jiangtang tiaozhi recipe randomized controlled trial
collection and banking of leukemia cells mds/aml

Conditions: Myelodysplastic Syndrome; Acute Myeloid Leukemia

Summary: the goal of this research study is to determine if it is feasible to collect leukemia cells from patients ahead of time (before they undergo further treatments) so that these cells (after being radiated so they will no longer grow or divide) can be given back to them as a cancer vaccine if/after the participant receives a bone marrow or blood stem cell transplant in the future. the purpose of the research study will be to collect, freeze and store leukemia calls from participants blood or bone marrow. this study is a companion study to a vaccine study.

* leukemia cells will be collected by one or more of the following methods: 1)routine blood draw 2)bone marrow aspirate 3) leukapheresis. the physician and study staff will determine which of the methods above is best suited for each participant. * after collection, the leukemia cells will be transported to the cell manipulation core facility (cmcf) at the dana-farber cancer institute, where they will be frozen until the time of vaccine administration.

Eligibility criteria:
inclusion criteria: * patients with aml will be eligible for banking at the time of relapse or primary induction failure or at the time of aml diagnosis they are 60 years of age or older, aml arising out of background mds or mpd or aml known with high risk cytogenetics * patients with mds-raeb-1 or raeb-ii, cmml-1 or cmml-ii * patients must have \>5% blast in bone marrow or peripheral blood * ecog performance status 0-2 * age greater than or equal to 18 years * reasonable likelihood, in the physician's opinion, that the patient will be a candidate for allogeneic stem cell transplant

Keywords: mds aml banking study
comparison of pregnancy outcomes in women with polycystic ovarian syndrome with and without glucophage

Conditions: Polycystic Ovarian Syndrome (PCOS); Pregnancy Outcomes

Summary: the goal of this clinical trial is to learn if glucophage (metformin) improves pregnancy outcomes in women with polycystic ovarian syndrome (pcos). it will also evaluate the safety of glucophage during pregnancy. the main questions it aims to answer are: does glucophage reduce the risks of early pregnancy loss, preterm delivery, and gestational diabetes? are there any medical problems associated with taking glucophage during pregnancy? researchers will compare glucophage with standard care (diet and exercise) to see if it improves pregnancy outcomes in women with pcos. participants will: take glucophage or follow a standard diet and exercise plan throughout pregnancy. attend regular follow-up visits for checkups, ultrasounds, and blood tests. have their pregnancy outcomes, such as fetal growth and gestational diabetes, recorded.

this randomized controlled trial aims to evaluate the effectiveness of glucophage (metformin) in improving pregnancy outcomes for women with polycystic ovarian syndrome (pcos). the study compares two groups: one receiving standard diet and exercise along with glucophage and another receiving only standard diet and exercise. outcomes such as early pregnancy loss, preterm delivery, gestational diabetes, intrauterine growth restriction, and fetal malformations will be assessed. participants will be enrolled during their first trimester and followed through delivery. data will be collected during regular follow-up visits, including ultrasound scans and oral glucose tolerance tests. the study will use statistical analysis to determine whether glucophage significantly improves maternal and fetal health outcomes compared to standard care. findings will help guide clinical management strategies for pcos during pregnancy.

Eligibility criteria:
inclusion criteria: pregnant females aged 18-40 years diagnosed with polycystic ovarian syndrome (pcos) before conception, as per operational definition. present in the 1st trimester at the booking visit. singleton fetus on booking scan between 5th to 13th week of gestation. exclusion criteria: females who do not give informed consent for follow-up. females with preeclampsia (bp ≥140/90 mmhg with proteinuria \>+1 on dipstick method). females already diagnosed with gestational diabetes (ogtt \>186 mg/dl). females already taking trial treatment (as per medical record). twin pregnancy or abnormal placenta (assessed on ultrasound). diagnosed hypertensives and diabetic patients.
validation of a multitask deep learning system at spine metastasis ct

Conditions: To Evaluate Performance of the DLS

Summary: 15 resident oncologists were conducted to evaluate the clinical efficacy of dls in multicenter. they were 1:1 randomly asked to independently read the test images without the assistance of dls software or with the assistance. area under the receiver operating characteristic curve (auc), sensitivity, and specificity of the dls were calculated with professional graders as the reference standard.


Eligibility criteria:
inclusion criteria: 1. pathology-proven diagnosis of solid tumor; 2. spinal ct scan indicating spinal metastasis with at least one lesion; 3. no previous surgery for spinal metastasis exclusion criteria: 1. spinal ct scans with no sagittal reconstruction; 2. the radiologist considered that the quality of ct image was unqualified.
an investigation into the efficacy of provodine topical cream as compared to 10% benzoyl peroxide wash for the treatment of hidradenitis suppurativa.

Conditions: Hidradenitis Suppurativa

Summary: the purpose of this study is to compare the efficacy of provodine™ topical cream to 10% benzoyl peroxide topical body wash for the treatment of early stage hidradenitis suppurativa.

hidradenitis suppurativa (hs) is a chronic, recurrent inflammatory disease of the skin. it typically manifests as nodules and abscesses that ultimately can progress to form deep sinus tracts, fistulas, and scarring. it affects areas of the body with apocrine gland bearing tissue, including the anogenital, axillary and inframammary regions. the lesions are often very painful and can chronically drain malodorous fluid, which can leave affected individuals uncomfortable and self-conscious, or even debilitated. the pathogenesis of this disease process is not fully understood, and the hs can be difficult to treat. measures such as topical antibiotic and antiseptic washes are generally thought to be beneficial for the treatment of early stage hs. although there have been no controlled trials for the treatment of hs, commonly used topical washes currently include benzoyl peroxide and chlorhexidine gluconate. provodine™ topical cream was designed to actively kill microbes on the skin for up to 6 hours without resulting in the irritation often associated with repetitive use of antimicrobial products. a blinded controlled comparison of provodine™ versus the current standard of benzoyl peroxide wash will not only allow for an alternative treatment for early stage hs but also provide an additional tool in the arsenal of treatments for this disease process.

Eligibility criteria:
inclusion criteria: * for inclusion, the subject must: 1. be at least 13 years old. 2. be otherwise healthy. 3. have a diagnosis of hs. 4. patients must have hurley stage i or stage ii hs 5. be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form. 6. agree to follow and undergo all study-related procedures. 7. if applicable, minors must have permission of legal guardian for participation in the study. exclusion criteria: * subjects who meet the following criteria will be excluded: 1. patients with hs hurley stage iii will be excluded from participation in the study 2. patients who are pregnant or breast feeding will not be able to take part in the study due to the unknown effects of the topical medications. 3. concomitant use of systemic or other topical treatments for hs not involved in current study. for cohort i, no washout period for systemic and/or topical medications will be required. for cohort ii, there will be a 14 day minimum washout period for systemic and topical treatments for hs. 4. any reason the investigator feels the patient should not participate in the study. 5. if a patient misses ≥ 2 consecutive study visits, the patient will be excluded from further participation in this trial. 6. history of allergy to iodine or benzoyl peroxide.

Keywords: hidradenitis suppurativa hs acne inversa velpeau's disease verneuil's disease
clopidogrel efficacy and acute coronary syndromes

Conditions: Acute Myocardial Infarction

Summary: the purpose of this study is to compare clopidogrel effectiveness between severe hemodynamically unstable versus stable patients with acute myocardial infarction.

clopidogrel exists in oral form only. as a prodrug, it has to be metabolized to the active form by cytochrome system in the liver. both facts could lead to lower efficacy of the drug in hemodynamically unstable patients, where splanchnic and liver hypoperfusion is present. we hypothesised that clopidogrel efficacy is insufficient in patients with acute myocardial infarction and severe hemodynamic instability. therefore we would like to compare the effect of clopidogrel in unstable stemi patients on mechanical ventilation with stable stemi patients.

Eligibility criteria:
inclusion criteria for unstable group: * acute stemi * mechanical ventilation * the need for catecholamine support. inclusion criteria for stable group: * acute myocardial infarction exclusion criteria for any: * previous treatment with clopidogrel * clopidogrel administration during transport by ambulance * known intolerance to clopidogrel * history of thrombocytopenia (\<150,000 platelets/ml) * pre-existing liver disease

Keywords: platelet vasp clopidogrel cardiogenic shock myocardial infarction percutaneous coronary intervention
serum procalcitonin study in the management of ventilated patients

Conditions: Ventilator Associated Pneumonia

Summary: the purpose of this study is to test a new method for diagnosing and monitoring ventilator-associated pneumonia, which is a major killer among icu patients. the method requires analysis of a small amount of the patient's blood for concentration of a hormone called procalcitonin.

ventilator-associated pneumonia is a leading cause of mortality in critically ill patients. the purpose of this study is to evaluate the relationship between the onset/progress/resolution of pneumonia and the levels of procalcitonin, a prohormone whose concentrations fluctuate in response to bacterial infection.

Eligibility criteria:
inclusion criteria: * are willing to give or who's proxy is willing to consent to be a study subject * are at least 18 years of age; * who are mechanically ventilated surgical intensive care unit patients. exclusion criteria: * participation in any investigational device or drug trial within 30 days prior to enrollment.

Keywords: ventilator associated pneumonia mechanically ventilated procalcitonin pneumonia scores
clinical investigation of the acrysof iq vivity extended vision intraocular lens (iol)

Conditions: Aphakia

Summary: the purpose of this study is to compare the visual disturbance profile of an intraocular lens (iol) using nondiffractive optics, the vivity iol, to two diffractive iols in subjects requiring bilateral cataract surgery. iols are implantable medical devices intended for long-term use over the lifetime of the cataract patient.

a total of 10 scheduled visits are planned. the visits include a screening visit, 2 operative visits, and 7 postoperative visits. both eyes will be implanted. the second eye implant will occur within 7-21 days of the first eye implant. the primary endpoint data will be collected at the month 3 visit. individual subject participation is expected to last 6-7 months. this study will be conducted in australia and new zealand.

Eligibility criteria:
inclusion criteria: * planned cataract removal in both eyes. * willing and able to complete all required postoperative visits. * able to understand, read and write english and willing to sign an approved statement of informed consent. * other protocol-defined inclusion criteria may apply. exclusion criteria: * women of childbearing potential, pregnant, intend to become pregnant, breastfeeding. * any eye condition, disease or pathology, other than cataract, that is expected to reduce postoperative best corrected distance visual acuity, as specified in the protocol. * ocular trauma or ocular surface disease that would affect study measurements. * patients who desire monovision correction. * other protocol-specified exclusion criteria may apply.

Keywords: cataracts extracapsular cataract extraction iol extended depth of focus visual disturbances presbyopia intraocular lens
effect of different anti-platelet strategies on the long-term outcome after sirolimus drug-eluting stent implantation

Conditions: Coronary Artery Disease

Summary: the study aims to assess the effectiveness of dual antiplatelet therapy, aspirin alone versus steeply discontinued clopidogrel plus aspirin in preventing clinical mace events.our subject is beyond a 12-month period patients receiving sirolimus drug-eluting stent implantation.

it is not clear that dual antiplatelet therapy is better than aspirin beyond 12-months period patients receiving sirolimus drug-eluting stent implantation. if aspirin plus clopidogrel reduced mace rates without increasing blood events, the investigators will evaluate risk-benefit ratio. the investigators will observe all cause mortality, nonfatal myocardial infarction, or clinical-driven target vessel revascularization tvr in a 1-year trial duration. in addition, strokes, stent thrombosis, cardiac re-hospitalizations, dialysis/hemofiltration, duration of hospitalization and bleeding events will be observed.

Eligibility criteria:
inclusion criteria: * age 18 years of older. * the latest pci with des implantation before 12 months (stents must be one or more sirolimus-eluting stents). * angiographically confirmed major epicardial vessels (\>=2.5mm in diameter) without significant stenosis or restenosis (\>=50%). * geographically accessible and willing to come in for required study visits. * signed informed consent. exclusion criteria: * the patient has a known hypersensitivity or contraindication to aspirin and clopidogrel. * severe congestive heart failure (class iii or iv according to nyha, or pulmonary edema) at the time of enrollment and within 12 months. * ef\<35% within 12 months. * severe cardiac valves disease, or idiopathic cardiomyopathy such as dilated cardiomyopathy, hypotrophic cardiomyopathy. other severe system diseases. * previous acs within 12 months. * previous stroke or transient ischemia attack within 12 months. * previous myocardial infarction and clinical-driven target vessel revascularization within 12 months. * current enrollment in another clinical trial. * suspected pregnancy. * big bleeding events within 12 months. * planned surgical procedure. * previous other type des implantation or bms implantation history. * extra-cardiac stent implantation history. * current or planned dialysis. * the patient has a known hypersensitivity or contraindication to statins. * current or planned high dose and long-term glucocorticoid treatment. * that is expected to limit survival to less than 1 years.

Keywords: dual antiplatelet therapy sirolimus drug-eluting stent major adverse cardiac events bleeding
injuries in swedish youth athletics. the klub-study.

Conditions: Athletics Injuries

Summary: it is well known that participation in sports activities as a youth has several health benefits, but at the same time, studies report that the risk is high to obtain injuries related to participation. there is, however, increasing evidence that many of these injuries can be prevented if necessary measures are taken. prospective studies are therefore needed to be able to plan and carry out measures to prevent the occurrence of injuries. the overall aim of the project klub is to study the prevalence and incidence of injuries among athletics youths aged 12-15 years. a particular focus will be placed on identifying factors associated with injury occurrence.

it is well known that participation in sports activities as a youth has several health benefits, but at the same time, studies report that the risk is high to obtain injuries related to participation. there is, however, increasing evidence that many of these injuries can be prevented if necessary measures are taken. so far, most studies examining sports injuries have been conducted on adult elite and among team sports, for example football, ice hockey and bandy. how injury patterns present in individual sports and among youth is not as well documented. a major problem in athletics is that studies have shown an almost identical prevalence and incidence of injury associated with athletics among both young and adult athletes. today there are very few published studies on international incidence of injuries among adolescent athletes in athletics and no describing the incidence in swedish athletics. these studies have different study design, definitions of injury and rather small groups of athletes, making it difficult to draw conclusions that can be the basis for prevention programs. what after all can be inferred from these previous studies is that injuries related to overuse seems to be most prevalent. prospective studies are therefore needed to be able to plan and carry out measures to prevent the occurrence of injuries. we intend to carry out an intervention study among athletics youths aged 12-15 years. before this is carried out, the investigators need to have adequate knowledge of the study population for the effective implementation of the intervention study. the overall aim of the project klub is to study the prevalence and incidence of injuries among athletics youths aged 12-15 years. a particular focus will be placed on identifying factors associated with injury occurrence. the knowledge obtained will be used to allow for injury prevention in the future.

Eligibility criteria:
inclusion criteria: * age 12-15 years * regularly participate in organized athletics training exclusion criteria: -

Keywords: prospective epidemiology track and field
carotid intima-media thickness as cardiovascular mortality predictor in peritoneal dialysis patients

Conditions: Myocardial Infarction

Summary: cardiovascular (cv) disease is the main cause of death in patients on dialysis. the aim of this study is the long-term prognostic values of carotid intima-media thickness and coronary flow reserve in cardiovascular mortality of peritoneal dialysis patients.

endothelial dysfunction (ed) is a precursor and cause of cardiovascular diseases. defining of endothelial thickness and coronary microvascular function could be useful for detecting ed. endothelial dysfunction could be assessed by coronary flow reserve (cfr), carotid intima media thickness (imt). repeating measurement of imt and cfr could be predictor of cardiovascular events and mortality in peritoneal dialysis patients.

Eligibility criteria:
inclusion criteria: * peritoneal dialysis patients whose followed up at least six months from october 1994 to october 2011 (for study group) * kidney transplant recipients whose followed up at least six months from october 1994 to october 2011 (for control group) exclusion criteria: * diabetes mellitus * valvular heart disease, * any prior coronary intervention and congestive heart failure * patients whose left anterior descending coronary artery (lad) could not be visualized adequately by doppler echocardiography were also excluded.

Keywords: peritoneal dialysis carotid intima-media thickness coronary flow reserve cardiovascular mortality